Changes in Hong Kong stocks | Duqi Pharmaceutical-B (06996) rose nearly 6%, and Sivio's two new drug supplements were approved by the Hong Kong Department of Health

The Zhitong Finance App learned that Deqi Pharmaceutical-B (06996) rose nearly 6%. As of press release, it had risen 5.34% to HK$4.34, with a turnover of HK$9.494,400.

According to the news, the Hong Kong Department of Health has approved the marketing applications of Sivio (Celinisol) for the treatment of multiple myeloma (in combination with bortezomib and dexamethasone, for adult patients who have received at least one treatment) and recurrent or refractory diffuse large B-cell lymphoma (as a single drug treatment plan for adult patients who have undergone at least two lines of systematic treatment and are not eligible for hematopoietic stem cell transplantation).

This approval marks the further expansion of Deqi Pharmaceuticals in the Hong Kong market and is of great significance to the company's business development. It not only highlights the continuous strengthening of the company's R&D and marketing capabilities in the biopharmaceutical field, but Sivio's approval will also meet the treatment needs of the Hong Kong market for diseases related to the Hong Kong market and enhance the company's competitiveness in the biotechnology industry.